Effects of Intraduodenal Infusion of the Bitter Tastant, Quinine, on Antropyloroduodenal Motility, Plasma Cholecystokinin, and Energy Intake in Healthy Men
| Autor: | Christine Feinle-Bisset, Wolfgang Meyerhof, Penelope C E Fitzgerald, Michael Horowitz, Tanya J. Little, Tongzhi Wu, Vida Bitarafan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Calorie media_common.quotation_subject Stimulation 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Gastrointestinal hormones Pylorus Cholecystokinin media_common Gastrointestinal tract Quinine business.industry Gastroenterology Appetite 3. Good health Endocrinology medicine.anatomical_structure 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Original Article Energy intake Neurology (clinical) business Hormone medicine.drug |
| Zdroj: | Journal of Neurogastroenterology and Motility |
| ISSN: | 2093-0879 |
| Popis: | Background/Aims Nutrient-induced gut hormone release (eg, cholecystokinin [CCK]) and the modulation of gut motility (particularly pyloric stimulation) contribute to the regulation of acute energy intake. Non-caloric bitter compounds, including quinine, have recently been shown in cell-line and animal studies to stimulate the release of gastrointestinal hormones by activating bitter taste receptors expressed throughout the gastrointestinal tract, and thus, may potentially suppress energy intake without providing additional calories. This study aims to evaluate the effects of intraduodenally administered quinine on antropyloroduodenal pressures, plasma CCK and energy intake. Methods Fourteen healthy, lean men (25 ± 5 years; BMI: 22.5 ± 2.0 kg/m2) received on 4 separate occasions, in randomized, double-blind fashion, 60-minute intraduodenal infusions of quinine hydrochloride at doses totaling 37.5 mg (“Q37.5”), 75 mg (“Q75”) or 225 mg (“Q225”), or control (all 300 mOsmol). Antropyloroduodenal pressures (high-resolution manometry), plasma CCK (radioimmunoassay), and appetite perceptions/gastrointestinal symptoms (visual analog questionnaires) were measured. Ad libitum energy intake (buffet-meal) was quantified immediately post-infusion. Oral quinine taste-thresholds were assessed on a separate occasion using 3-alternative forced-choice procedure. Results All participants detected quinine orally (detection-threshold: 0.19 ± 0.07 mmol/L). Intraduodenal quinine did not affect antral, pyloric or duodenal pressures, plasma CCK (pmol/L [peak]; control: 3.6 ± 0.4, Q37.5: 3.6 ± 0.4, Q75: 3.7 ± 0.3, Q225: 3.9 ± 0.4), appetite perceptions, gastrointestinal symptoms or energy intake (kcal; control: 1088 ± 90, Q37.5: 1057 ± 69, Q75: 1029 ±7 0, Q225: 1077 ± 88). Conclusion Quinine, administered intraduodenally over 60 minutes, even at moderately high doses, but low infusion rates, does not modulate appetite-related gastrointestinal functions or energy intake. (J Neurogastroenterol Motil 2019;25:413-422) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|